Oxford Drug Design announced today success in securing funds, totalling over £8m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the UK Department of Health and Social Care Small Business Research Initiative (SBRI) and equity investment led by o2h Ventures. These funds will be used to advance our dual-target aminoacy-tRNA synthetase inhibitor (DaaRSi) project, which is […]
Oxford Drug Design has raised nearly $2m (£1.5m) of private investment to enable it to progress a novel antibacterial programme and continue to build its proprietary platform. The funding, which will also help finance the company’s commercial and research and development (R&D) activities, was supported by both existing shareholders including IP Group plc as well […]
Oxford Drug Design (formerly InhibOx) has started work on a $1.1m (£900k) grant funded project to develop novel antibiotics.